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Abstract
Sphingosine kinases (SK) catalyze the phosphorylation of proapoptotic sphingosine to the prosurvival factor sphingosine 1-
phosphate (S1P), thereby promoting oncogenic processes. Breast (MDA-MB-231), lung (NCI-H358), and colon (HCT 116)
carcinoma cells were transduced with shRNA to downregulate SK-1 expression or treated with a pharmacologic SK-1
inhibitor. The effects of SK-1 targeting were investigated by measuring the level of intracellular sphingosine, the activity of
protein kinase C (PKC) and cell cycle regulators, and the mitotic index. Functional assays included measurement of cell
proliferation, colony formation, apoptosis, and cell cycle analysis. Downregulation of SK-1 or its pharmacologic inhibition
increased intracellular sphingosine and decreased PKC activity as shown by reduced phosphorylation of PKC substrates. In
MDA-MB-231 cells this effect was most pronounced and reduced cell proliferation and colony formation, which could be
mimicked using exogenous sphingosine or the PKC inhibitor RO 31-8220. SK-1 downregulation in MDA-MB-231 cells
increased the number of cells with 4N and 8N DNA content, and similar effects were observed upon treatment with
sphingosine or inhibitors of SK-1 or PKC. Examination of cell cycle regulators unveiled decreased cdc2 activity and
expression of Chk1, which may compromise spindle checkpoint function and cytokinesis. Indeed, SK-1 kd cells entered
mitosis but failed to divide, and in the presence of taxol also failed to sustain mitotic arrest, resulting in further increased
endoreduplication and apoptosis. Our findings delineate an intriguing link between SK-1, PKC and components of the cell
cycle machinery, which underlines the significance of SK-1 as a target for cancer therapy.
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Introduction
The cellular sphingolipid signaling pathway is a highly
conserved balanced system comprising ceramide and sphingosine
with proapoptotic functions on the one hand, and sphingosine-1-
phosphate (S1P) promoting cell survival and proliferation on the
other hand [1]. Elevated S1P favors tumor development and
progression as it inhibits apoptosis and promotes cell proliferation,
survival and migration. The level of intracellular S1P is
maintained by sphingosine kinase 1 (SK-1) and the less well
defined isoform sphingosine kinase 2 (SK-2) [2,3]. SK-1 is
overexpressed in many human tumors [4,5] where it contributes
to malignant progression and thus represents a promising
molecular target for cancer therapy [6].
The recent finding that SK-1, SK-2 and the S1P5 receptor show
centrosomal localization in cells has raised speculations about a
direct role of the kinases and their metabolites in cell cycle
regulation [7]. Whereas ceramide was shown to inhibit prolifer-
ation by inducing cell cycle arrest at the G0/G1 boundary [8,9],
sphingosine inhibits proliferation by inhibition of PKC [10,11].
Interestingly, other studies also demonstrated that glycosphingo-
lipids may function as inhibitors or stimulators of PKC activity
[12], though the molecular details underlying this differential
effects are still unclear. For sphingosine, biochemical analysis
unveiled that it inhibits PKC by preventing the binding of phorbol
esters without affecting the catalytic domain [13].
The serine/threonine kinase PKC is the major cellular target of
tumor promoting phorbol esters and thus considered crucial for
carcinogenesis [14]. It consists of a family of isoenzymes which are
divided into three classes based on their activation requirements
[15]. PKCs induce a variety of fundamental biological effects
including cell proliferation and differentiation, membrane trans-
port and gene transcription. Many of these effects drive malignant
progression and result either directly from activated PKC or
indirectly through its downstream effectors [16]. Consequently,
PKC has been investigated as a target for cancer therapy, and a
myriad of drugs from small molecule inhibitors to antisense
oligonucleotides has been evaluated for therapeutic efficacy in
preclinical tumor models and oncology trials [17]. Members of the
PKC family were also found to be involved in cell cycle regulation
by interfering in checkpoint functions [18,19].
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dependent kinases and their cyclin substrates. p34cdc2, also
named Cdk1, together with cyclin B1 constitutes the mitosis
promoting factor (MPF) which is crucial for G2/M transition and
execution of mitosis [20–22]. Interestingly, both subunits of the
MPF can be phosphorylated by PKC and PKC inhibitors may
thus indirectly affect cdc2 activity too [23]. The DNA damage
effector checkpoint kinase 1 (Chk1) is another multifunctional
kinase of the cell cycle machinery which regulates the DNA
damage response and is further required for spindle checkpoint
function during early mitosis and for cytokinesis before cell
division is completed [24]. In mitotic cells abrogation of Chk1
causes the typical defects including chromosome misalignment,
cytokinetic regression and endoreduplication [25].
The therapeutic potential of targeting SK-1 and its product S1P
in cancer has been reported in various preclinical studies [2]. We
previously demonstrated that downregulation of SK-1 in carcino-
ma cells induced oxidative stress, which facilitated apoptosis
induced by DNA damaging agents [26]. Here, we demonstrate
that in carcinoma cells of various histotypes loss of SK-1 activity by
genetic or pharmacologic inhibition compromises PKC due to
intracellular sphingosine accumulation and establish a link
between SK-1, PKC and M phase-specific cell cycle regulators,
which may help improving our understanding of sphingolipid
signaling in cancer.
Results
SK-1 Knockdown Results in Sphingosine Accumulation
SK-1 regulates the sphingosine/S1P ratio and thus the
commitment of cells to survival or death. We used carcinoma
cell lines of different histotypes and with different SK-1 expression
levels to stably downregulate SK-1 using shRNA, and measured
the intracellular accumulation of sphingosine by mass spectrom-
etry. As shown in Fig. 1A and Fig. S1A, in MDA-MB-231, NCI-
H358, and HCT 116 cells vector-based RNAi strongly reduced
SK-1 protein and mRNA expression (SK-1 kd cells) compared to
the respective untreated wild-type (wt) cells. As further controls,
MDA-MB-231 cells treated with empty virus or overexpressing
SK-1 (SK-1 ov) were included, which showed no effect on SK-1
expression or strong overexpression, respectively. SK-2 expression
was not modulated in SK-1 kd cells as shown in Fig. S1B.
Interestingly, all SK-1 kd cells contained higher levels of
sphingosine compared to their counterpart control cells and this
increase was most pronounced in MDA-MB-231 SK-1 kd cells
(Fig. 1B). Transfection of MDA-MB-231 cells with empty virus as
additional control did not increase the level of sphingosine,
indicating that they behaved like wt cells. On the other hand,
sphingosine was reduced by 90% in MDA-MB-231 cells
overexpressing SK-1 (SK-1 ov). The MDA-MB-231 cell line also
expressed the highest basal level of SK-1, indicating that it was
most susceptible to the manipulation and probably strongly
depends on SK-1 function to keep the sphingolipid rheostat in
check [26]. Ceramide levels were not altered in SK-1kd cells of all
histotypes compared to wt (Fig. S1C). Similar to the genetic
knockdown of SK-1, pharmacologic manipulation of SK-1 activity
using the SK-1 inhibitor SKI II also increased sphingosine levels in
the cell lines in correlation with their basal SK-1 expression
(Fig. 1C).
Elevated Sphingosine in SK-1 kd Cells Inhibits PKC
Sphingosine can act as an endogenous inhibitor of PKC [27]
and it was therefore of interest to investigate PKC activity in the
three SK-1 kd carcinoma cell lines. Since direct measurement of
PKC isoenzyme-specific activity is not reliable, we indirectly
measured total PKC activity by detection of changes in the
phosphorylation status of various isoenzyme-specific substrates. To
this end, a phospho-Ser PKC substrate antibody was used which
recognizes target proteins phosphorylated at the PKC consensus
site R/K-X21-S-X+1-R/K, where X+1 is a hydrophobic residue.
In all SK-1 kd cell lines, a distinct subset of bands was reduced
compared to the respective wt control cells (Fig. 2A). Specifically,
reduced phosphorylation upon SK-1 downregulation was found
for bands at 130, 80, 68, 55, and 36 kDa in MDA-MB-231 cells, at
130, 55, 50, and 34 kDa in NCI-H358 cells, and at 95, 80, 70, and
56 kDa in HCT 116 cells. The differences in the phosphorylation
pattern and intensities among the different cell lines suggest that
either different PKC isoenzymes were involved or that PKC
isoenzymes and/or their substrates were differentially expressed.
As shown for MDA-MB-231 cells, treatment with exogenous
sphingosine (20 mM) resulted in a very similar pattern of reduced
substrate phosphorylation compared to the SK-1 kd cells, thus
confirming the inhibitory effect of this sphingolipid on PKC
activity. In addition, we examined the levels of expression of
different PKC isoenzymes in MDA-MB-231 wt, SK-1 kd and SK-
1 ov cells and could not detect any differences (Fig. S2).
To better discriminate between the various PKC isoenzymes
inactivated by sphingosine, the wt cell lines were treated with the
inhibitor CGP 41-251, which targets the calcium-dependent PKC
a, b, and c isoenzymes [28], and the pan-PKC inhibitor Ro 31-
8220, which targets all isoenzymes with the exception of PKCf
[29]. Fig. 2B shows that in all carcinoma cell lines Ro 31-8220, but
not CPG 41251, effectively reduced phosphorylation of the PKC
substrates. The same data were obtained under conditions of
serum starvation of cells when pretreatment with Ro 31-8220
effectively prevented PKC from TPA activation, whereas CPG
41–251 was only partially effective (Fig. 2B). This finding identified
calcium-independent PKC isoenzymes as the major targets
inhibited in SK-1 kd cells.
As a reverse approach we stimulated MDA-MB-231 wt and SK-
1 kd cells with phorbol ester (TPA) as an activator of PKC [14,28]
and examined which PKC substrates became phosphorylated. As
shown in Fig. 2C, stimulation with TPA increased the phosphor-
ylation in a number of bands with the most pronounced alterations
occurring at the same size (130, 80, 55, 36 kDa) where
phosphorylation was decreased in SK-1 kd cells and in wt cells
upon treatment with exogenous sphingosine (Fig. 2A). This
confirms that these bands indeed represent relevant PKC
substrates. Similar results were obtained with wt cells in the
presence of the SK-1 inhibitor SK I II (data not shown).
Furthermore, blocking protein degradation in SK-1 kd cells using
lactacystin (LC) failed to restore substrate phosphorylation
(Fig. 2C), indicating that reduced phosphorylation was not due
to substrate degradation but rather to inhibition of PKC and/or
decreased PKC substrate expression.
Inversely, in MDA-MB-231 cells overexpressing SK-1 phos-
phorylation of the same PKC substrates which were inhibited in
SK-1 kd cells was increased compared to wt cells (Fig. 2D). This
further confirms the ability of SK-1 to stabilize PKC activity,
probably by depletion of intracellular sphingosine.
Reduced Colony Formation of SK-1 kd Cells can be
Mimicked with Sphingosine or PKC Inhibitors
The cellular effects associated with PKC inhibition in tumor
cells include decreased proliferation, cell cycle disruption and
apoptosis [30]. Since downregulation of SK-1 increases intracel-
lular sphingosine, which inhibits PKC and decreases cell
proliferation and survival, the colony formation of MDA-MB-
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Figure 1. Downregulation of SK-1 results in sphingosine accumulation. (A) MDA-MB-231, NCI-H358, and HCT 116 cells were transduced with
lentiviral SK-1 shRNA to downregulate SK-1 expression (SK-1 kd) or left untreated (wild-type, wt). MDA-MB-231 cells transduced with empty virus or
transfected with the SK-1 cDNA for overexpression (SK-1 ov) are shown for comparison. Cell lysates were prepared and SK-1 protein expression was
detected by Western blotting using antibodies against SK-1 (dilution 1:1000) or GAPDH (dilution 1:2000) as loading control. The two SK-1 splice
variants SK-1a and SK-1b run at 43 and 51 kDa, respectively. The films were digitized and for each protein lane a density blot was measured. Each
value in the graph represents the mean 6 SD band density for each group (n=3); ***p,0.001 compared to wt cells. (B) cellular sphingosine was
determined in the genetically modified SK-1 kd carcinoma cell lines, in the respective wt cells, and additional MDA-MB-231 control cells as described
above (empty virus transfected, SK-1 ov). Lipid extractions were performed and sphingosine was quantified by mass spectrometry. Data are means 6
SD (n=3); *p,0.05, **p,0.01, ***p,0.001 compared to wt cells. (C) endogenous sphingosine in the wt carcinoma cell lines upon treatment with the
SK-1 inhibitor SK I II (10 mM) or DMSO as vehicle control for 24 h. Quantification was done as above. Data are means 6 SD (n=3); *p,0.05, **p,0.01
compared to DMSO treated cells.
doi:10.1371/journal.pone.0039209.g001
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inhibitors was measured and compared to SK-1 kd cells. As shown
in Fig. 3, treatment with either sphingosine, CGP 41-251 or Ro
31-8220 reduced colony formation in a dose-dependent manner.
CGP 41-251 more effectively attenuated clonal expansion than Ro
31-8820, which might be due to its negative effect on other kinases
involved in cell proliferation [31,32]. Compared to SK-1 kd cells a
similar degree of inhibition was achieved with .0.5 mM sphingo-
sine, 0.01 mM CGP 41-251 or with 5 mM Ro 31-8220. From this
we conclude that intracellular sphingosine and PKC are key
players in controlling the clonal expansion of carcinoma cells.
SK-1 kd Cells Enter Mitosis but Fail to Divide
Sphingolipids and PKC are implicated in the control of
cytokinesis and mitotic exit [33,34]. To investigate whether the
decreased proliferation and clonal expansion of MDA-MB-231
SK-1 kd and of wt cells upon treatment with sphingosine or PKC
inhibitors was due to mitotic defects and cytokinetic regression, the
DNA content was measured. Compared to wt cells there was an
almost complete lack of SK-1 kd cells with a 2N DNA content
whereas the fraction of cells with 4N and 8N was substantially
increased (Fig. 4A). The data of co-treatment with SK I II
inhibitor and sphingosine shown in Fig. S3A also suggest that
sphingosine and inhibition of SK-1 are responsible for the
accumulation of cells in S phase and with 4N and 8N DNA
content after 24 h of treatment. Moreover, after 48 h and 72
hours of treatment we observed an accumulation of cells in the
SubG1 peak, indicating increased apoptosis (Fig. S3A, Fig. S3B).
As shown in Fig. 4B, cytokinesis failure in MDA-MB-231 SK-1 kd
cells was also confirmed by an increased number of giant cells with
substantially enlarged nuclei or multinucleation compared to wt
cells. The diameter of the SK-1 kd cells was increased by 30%
(Fig. 4C) and nuclei with diameter less than 10 mM were almost
absent in kd cells (Fig. 4D). Quantification of phospho-histone H3
revealed no decrease in the overall number of mitotic cells (data
not shown).
By tendency, short term treatment with sphingosine, the SK-1
inhibitor SK I II, the PKC inhibitor Ro 31-8220, or with SK I II
and sphingosine simultaneously (Fig. S3A) or sphingosine alone
(data not shown) also increased endoreduplication in MDA-MB-
231 wt cells (data not shown). In contrast to genetic manipulation
of cells with shRNA where SK-1 was permanently decreased and
cells were allowed to adapt over time, treatment with the
pharmacologic inhibitors resulted in substantial toxicity thereby
precluding selection of a stable population.
SK-1 Downregulation Compromises cdc2 and Chk1
Function
To understand the molecular mechanism underlying endor-
eduplication and cytokinesis failure in MDA-MB-231 SK-1 kd
Figure 2. Downregulation of SK-1 increases sphingosine which
inhibits PKC. (A) lysates were prepared from MDA-MB-231, NCI-H358,
and HCT 116 wt and SK-1 kd cells, and analyzed for PKC activity by
Western blotting using antibodies against various p(Ser) PKC substrates
(dilution 1:1000) or GAPDH (dilution 1:2000) as loading control. MDA-
MB-231 cells treated with sphingosine or DMSO vehicle control were
analyzed for comparison. (B) cells were treated with the PKC inhibitors
CGP 41-251 (300 nM) or Ro 31-8220 (1 mM) or with DMSO as control for
24 h before collection of lysates or quiescent MDA-MB-231 wt cells
were pretreated for 4 h with the PKC inhibitors Ro 31-8220 (1 mM), CGP
41-251 (300 nM) or DMSO as control. Thereafter, cells were stimulated
with the PKC activator TPA (200 nM) for 15 min. and lysates were
analyzed for p(Ser) PKC substrates as described above. (C) quiescent
MDA-MB-231 wt and SK-1 kd cells were stimulated with the PKC
activator TPA (200 nM) for 15 min, treatment of SK-1 kd cells with
lactacystin (20 mM for 24 h) was used to control for protein
degradation. Lysates were analyzed for p(Ser) PKC substrates as
described above. (D) MDA-MB-231 wt and SK-1 overexpressing (SK-1
ov) cells were analyzed for p(Ser) PKC substrates as described above.
doi:10.1371/journal.pone.0039209.g002
Targeting SK-1 Compromises PKC and Cytokinesis
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39209cells, we examined the expression and phosphorylation of cyclin
B1 and cdc2 by Western blotting. As shown in Fig. 5A, there was
no increase in the level of total cdc2, cyclin B1, and phospho-
cyclin B1(Ser133) in SK-1 kd cells compared to MDA-MB-231 wt
cells. However, we found a 2-fold increase in the inhibitory
phosphorylation of cdc2(Tyr15) compared to wt cells and a 4-fold
increase in the inhibitory phosphorylation of cdc2(Tyr15) com-
pared to SK-1 ov cells. Inversely, Tyr15 phosphorylation was
reduced 4-fold in SK-1 ov cells compared to SK-1 kd cells and 2-
fold compared to wt cells.
Decreased cdc2 activity may compromise cell cycle progression
and cytokinesis as recently demonstrated using the cdc2-specific
inhibitor RO 3306 [22]. Indeed, as shown in Fig. 5B treatment of
MDA-MB-231 wt cells with RO 3306 also induced a massive loss
of cells with 2N DNA content and concomitantly increased the
number of 4N and .4N cells, resulting in a profile reminiscent of
SK-1 kd cells.
Furthermore, we examined expression of the checkpoint kinase
Chk1, which is essential during mitosis and cytokinesis to complete
cell division. Figs. 5C and 5D show that in SK-1 kd cells Chk1
expression was indeed decreased on the mRNA and protein level
compared to wt cells. This suggests that the mitotic and cytokinetic
defects of SK-1 kd cells resulted from the combined loss of cdc2
and Chk1 function.
SK1 Downregulation Compromises Spindle Checkpoint
Function
Chk1 expression is reduced in SK-1 kd cells, which may
compromise spindle checkpoint function [35] and thus sensitize
cells to spindle-targeted chemotherapy. To test this possibility,
MDA-MB-231 wt and SK-1 kd cells were treated with taxol and
apoptosis was measured by annexin V staining. The data depicted
in Fig. 6A confirm that SK-1 kd cells were clearly more sensitive to
taxol-induced apoptosis than their wt counterparts. This effect was
independent of ceramide, which was not increased in SK-1 kd cells
(data not shown). Further analysis revealed that 24 h upon taxol
treatment the level of phospho-histone H3 as a mitotic marker
decreased (Fig. 6B), indicating that less SK-1 kd cells accumulated
in the M phase compared to wt cells and that their mitotic exit was
enforced.
In addition, in a complementary viability assay we investigated
the ability of sphingosine and the SK-1 inhibitor SK I II to
sensitize MDA-MB-231 wt cells to taxol. As shown in Fig. 6C,
combining taxol and SK I II resulted in an additive cytotoxic effect
on cells, which was even more than additive for the combination of
taxol and sphingosine.
These findings confirm that targeting SK-1 in carcinoma cells
generates an unfavorable mitotic environment with the potential
to increase the efficacy of taxane-based chemotherapy.
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Figure 3. Inhibition of PKC decreases colony formation of
carcinoma cells. MDA-MB-231 wt cells were seeded in 60 mm
diameter dishes at a density of 700 cells per dish in cell culture
medium. After 24 h cells were treated with various concentrations of
the PKC inhibitors CGP 41-251, Ro 31-8220 or with sphingosine, DMSO
was used as vehicle control. Colony formation of SK-1 kd cells
(untreated) incubated under identical conditions is shown for
comparison. Cells were incubated for another 14 d before colonies
were stained with 2% crystal violet and counted using a ColCountTM
(Mammalian Cell Colony Counter, Oxford Optronix). Only colonies
containing more than 50 cells were evaluated. Data are means 6 S.D.
(n=3); *p,0.05, **p,0.01, ***p,0.001 compared to the DMSO control
values.
doi:10.1371/journal.pone.0039209.g003
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We demonstrate that downregulation of SK-1 in various
carcinoma cell lines leads to intracellular accumulation of
sphingosine, a bioactive lipid with proapoptotic potential, whereas
the level of ceramide was not affected. This effect was most
pronounced in MDA-MB-231 cells. Since these cells exhibited the
highest basal level of SK-1, one might speculate that this is
necessary to keep the amount of the proapoptotic substrate in
check. The relative concentrations of the sphingolipid metabolites
S1P, sphingosine, and ceramide maintain a rheostat implicated in
cell death and survival [2]. As shown previously, SK-1 knockdown
in carcinoma cells not only increases intracellular sphingosine but
conversely also depletes the pool of prosurvival S1P, resulting in
growth inhibition and apoptosis [9,26]. In contrast to sphingosine,
S1P cannot enter into cells. Although it also acts as a survival
factor by binding to cognate receptors on the cell surface, this is
independent of the biological effect of intracellular S1P.
Interestingly, we found that in all three SK-1 kd carcinoma cell
lines accumulation of sphingosine decreased PKC activity and this
effect could be mimicked by the addition of exogenous sphingosine
to cells. On the other hand, PKC activity was increased in cells
overexpressing SK-1. The ability of sphingosine to inhibit PKC by
interaction with its regulatory domain was first described by
Hannun et al. [36] and later studies demonstrated a direct
competition of sphingosine with phorbol ester binding to PKC
[11]. However, so far the biological relevance of the SK1-PKC
connection has not been investigated in the context of SK-1-
targeted cancer therapy. PKC enzymes are major players in the
regulation of cell proliferation and survival with distinct biological
roles and cell type specificities. Despite many years of intensive
research in the field, the implication of its various isoforms in
cancer is still unclear [30]. Here, we measured Ser phosphoryla-
tion of various PKC substrates as a common approach to
determine cellular PKC activity [37,38]. Although we could not
fully dissect the distinct PKC isoforms inhibited by sphingosine in
our carcinoma cells, using selective inhibitors we excluded a and
b, and identified Ca
2+-independent isoforms as major targets. The
effect of CGP 41-251 on colony formation without detectable
activity in the p-Ser-PKC substrate assay is likely due to inhibition
of other survival kinases required for cell proliferation [31,32].
Taking the plethora of biological effects of PKC into account, we
conclude that SK-1 owes its oncogenic potential to the increased
production of prosurvival S1P, which at the same time prevents
accumulation of the proapoptotic substrate sphingosine and its
detrimental effect on PKC. Thus, SK-1 connects to PKC-
controlled cell survival pathways by regulating the intracellular
level of sphingosine as a biological PKC inhibitor. Indeed, in terms
of proliferation, colony formation and overall viability SK-1 kd
cells behaved similar to cells treated with PKC inhibitors
[37,39,40]. Conversely, PKC can act as an upstream regulator
of SK-1 as it was shown that in HEK cells phorbol ester not only
activated PKC but also SK-1, and inhibition of PKC on the other
hand impaired SK-1 function by preventing its translocation to the
plasma membrane [41]. Similarly, in renal mesangial cells
inhibition of PKC also decreased SK-1 expression and attenuated
its activation by growth factors [42].
From all three carcinoma cell lines we established sublines in
which SK-1 was stably downregulated by vector-based RNAi.
Alternatively, we used a pharmacologic SK-1 inhibitor SK I II [5]
to measure the short term effects of SK-1 loss. In both systems, the
level of intracellular sphingosine increased compared to untreated
cells. Not unexpectedly, differences in the effect of the two SK-1
targeting strategies were observed only in terms of the strength of
the cell response, but not by tendency. This was probably due to
selection of shRNA-transduced cells which had adapted to survive
without SK-1, whereas in contrast, selection of a stable SK-1
low
population using the SK I II inhibitor failed due to increasing
toxicity over time.
Apart from the loss of PKC activity the SK-1 kd carcinoma cells
may contain less S1P, a survival factor maintaining constant cross-
talk with other major growth factors [43,44]. Recently, SK-1 was
found to localize to centrosomes together with the S1P5 receptor
[7]. Whether S1P is produced in the nucleus and whether its
mitogenic activity can directly affect the cell cycle machinery
remains to be demonstrated. Here, we show that in MDA-MB-231
cells, which showed the strongest response to SK-1 downregula-
tion in terms of sphingosine generation and PKC inhibition, loss of
SK-1 was accompanied by endoreduplication and the formation of
giant cells with enlarged nuclei or multinucleation. Typically, these
cells showed mitotic defects comprising spindle checkpoint and
cytokinesis failure reminiscent of cells in which other mitosis
regulators such as Aurora B kinase are compromised [45].
However, we did not find evidence for the modulation of Aurora
B in SK-1 kd cells (Fig. S4). Again, similar but weaker effects were
observed upon short-term treatment with sphingosine or the PKC
inhibitor RO 31-8220, which for reasons of toxicity could not be
used in long-term assays to select a viable and stable SK-1
low cell
population. However, despite an increasing number of cells with
4N DNA content, we could not find signs of increased
endoreduplication. The ability of sphingosine and staurosporine
to induce G2/M arrest was also described for other cell types
[10,46]. One might thus speculate that this was a transitional
phenomenon reflecting early effects of PKC inhibition in this cell
population. Our molecular analysis unveiled that the activity of
cdc2, one of the components of the M phase promoting factor
(MPF) required to enter mitosis and prevent premature exit
without completion of cytokinesis [21,22,47], was decreased in
MDA-MB-231 cells upon SK-1 downregulation or sphingosine
treatment. Conversely, cdc2 activity was increased in cells
overexpressing SK-1. It is possible that the decreased cdc2 activity
in SK-1 kd cells was due to inhibition of PKC, which was
previously shown to activate the MPF [23].
In addition to decreased cdc2 activity, expression of Chk1 was
also reduced in MDA-MB-231 SK-1 kd cells. Since Chk1 delays
entry of cells with damaged or unreplicated DNA into mitosis [48],
one might expect that SK-1 kd cells are more susceptible to the
lethal effect of DNA damage. In fact, the rate of apoptosis in SK-1
cells was moderate in the absence of cytotoxic treatment and
analysis of Beclin 1 (Atg 6) expression did not provide evidence for
increased autophagy (Fig. S4). The cells could be propagated,
albeit with a slower growth rate than wt cells. Since MDA-MB-231
cells lack functional p53, they have a deficient post-mitotic
Figure 4. Downregulation of SK-1 induces endoreduplication. (A) MDA-MB-231 wt cells and SK-1 kd cells were stained with propidium iodide
and DNA content was measured by flow cytometry using a FACSCalibur flow cytometer and the Cell Quest software for data processing. (B) confocal
microscopy of MDA-MB-231 wt and SK-1 kd cells upon actin (red) and nuclear staining (blue) using TRITC-labeled phalloidin (dilution 1:1000) and
DAPI, respectively. (C) calculation of the nuclear size of SK-1 kd cells relative to wt cells. (D) quantification of cells with nuclei in different size ranges
(,10 mM, .10 mM, .15 mM). Data are means 6 SD of three independent experiments; **p,0.01, ***p,0.001 compared to MDA-MB-231 wt cells
values.
doi:10.1371/journal.pone.0039209.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39209Figure 5. Downregulation of SK-1 inhibits cdc2 activity and decreases Chk1 expression. (A) lysates from MDA-MB-231 wt, SK-1 kd, and SK-
1 overexpressing cells (SK-1 ov) were subjected to Western blotting using antibodies against total cdc2 (dilution 1:2000), phospho-cdc2(Tyr15)
(dilution 1:1000), total cyclin B1, and phospho-cyclin B1(Ser133) (dilution 1:1000). The films were digitized and for each protein lane a density blot was
measured. Each value in the graph represents the mean 6 SD band density for each group (n=3); ***p,0.001 compared to wt cells (B) MDA-MB-231
wt cells were treated with the cdc2 inhibitor RO 3306 (9 mM) or DMSO as vehicle control for 24 h, stained with propidium iodide and DNA content
was measured as described in Fig. 4. (C) Chk1 mRNA expression in MDA-MB-231 wt and SK-1 kd cells was measured by quantitative real-time PCR and
data were normalized to 18S rRNA. ***p,0.001 compared to wt values. (D) Chk1 protein expression in MDA-MB-231 wt and SK-1 kd cells detected by
Western blotting using antibodies against Chk1 (dilution 1:500) or GAPDH (dilution 1:2000) as loading control. The films were digitized and for each
protein lane a density plot was measured. Each value in the graph represents the mean 6 SD band density for each group (n=3); **p,0.01
compared to wt cells.
doi:10.1371/journal.pone.0039209.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39209checkpoint and also processes of depolyploidization might be
involved which limit the number of cells undergoing cell death by
mitotic catastrophe [49]. On the other hand, we previously found
that SK-1 knockdown in carcinoma cells facilitates apoptosis
induction by DNA damage [26]. Recently, reduced expression of
Chk1 and consequently sensitization to ionizing radiation was
described in cells depleted for S1P by transfection of S1P lyase
[50]. It is thus tempting to speculate that S1P somehow connects
to the cell cycle machinery via Chk1. Even more relevant for the
present study is that Chk1 is also required for spindle checkpoint
function [24,25], and its loss of function may cause premature
mitotic entry followed by metaphase block, misalignment of
chromosomes, kinetochore defects, and cytokinetic regression
[25,35]. Therefore, in MDA-MB-231 SK-1 kd cells the impaired
function of the two M phase regulators cdc2 and Chk1 together
likely aggravates mitotic defects and reduces cell viability,
particularly upon spindle-targeted chemotherapy. Evidence for
such a lethal cooperation was also provided by the increased
apoptosis of SK-1 kd cells upon treatment with taxol, and the
more than additive cytotoxic effect when the PKC inhibitor
sphingosine and the SK-1 inhibitor were combined with taxol.
Facilitation of apoptosis was independent of ceramide, which did
not increase upon SK-1 downregulation.
Altogether, our data demonstrate that downregulation of SK-1
in carcinoma cells leads to intracellular accumulation of sphingo-
sine which inhibits PKC. Inhibition of PKC in SK-1 kd cells
reduced proliferation and viability, and was accompanied by
decreased cdc2 and Chk1 function, which compromised spindle
checkpoint function and cytokinesis. More investigations are
warranted to further delineate the intriguing connection between
SK-1, PKC and the mitosis machinery.
Materials and Methods
Antibodies and Reagents
Hyperfilm MP, nitrocellulose membranes, secondary horserad-
ish peroxidase-coupled IgG, and enhanced chemiluminescence
reagents were obtained from GE Health Care Systems GmbH
(Glattbrugg, Switzerland). 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)
thiazole (SKI II), Taxol (paclitaxel), Aurora B antibody and
TRITC-labeled phalloidin for actin staining were from Sigma-
Aldrich (Buchs, Switzerland). Antibodies against phospho-Ser–
PKC substrate, PKD/PKC m, phospho-cdc2(Tyr15), total cdc2,
phospho-cyclin B1(Ser133), total cyclin B1, total Histone H3 and
GAPDH were obtained from Cell Signaling (supplied by
Bioconcept, Allschwil, Switzerland). The antibodies against PKC
H, l, i, f were from Transduction Laboratories (San Diego,
California). Synthetic peptides based on the C-terminal sequence
of PKC a (SYVNPQFVHPILQSAV), PKC e (NQEEFKGFSYF-
GEDLMP) and PKC d (KGFSFVNPKYEQFLE) were synthe-
sized on an ARI 431 peptide synthesizer, coupled to keyhole
limpet hemocyanin by glutaraldehyde and used to immunize
rabbits. The detailed characterization of anti- PKC a, e, d
antibodies is described elsewhere [28,51–54]. The antibody
against phospho-histone H3(Ser10) was from Millipore (supplied
by Lubioscience, Luzern, Switzerland). Antibodies against Beclin 1
(Atg 6) and Chk1, D-erythro-sphingosine and the PKC inhibitor
Ro 31-8220 were obtained from Santa Cruz Biotechnology
(supplied by LabForce AG, Nunningen, Switzerland). The
antibody against human SK-1 was generated as described [55].
To generate the polyclonal anti-human SK-2 antibody, two
synthetic peptides, NGHLEAEEQQDQRPD and
CLPGDGEITPDLLPRP based on the sequence of human SK-2
(accession number: NM_020126) were synthesized and coupled to
keyhole-limpet hemocyanin, and used to immunize rabbits. The
antiserum denoted #65 was characterized using transiently
human SK-2 overexpressing HEK293 cell lysates. Western blot
analysis revealed one single band at 68 kDa. Recombinant GFP-
labeled annexin V was kindly provided by Dr. T. Kaufmann
(Institute of Pharmacology, Bern). Glycergel Dako mounting
medium was supplied by DiaLine AG (Lausen, Switzerland).
Lactacystin, PKC inhibitor CGP 41-251 and the cdc2 inhibitor
RO-3306 were from Merck Biosciences (Darmstadt, Germany).
Carcinoma Cell Lines and Cell Culture
Cell culture media, serum and supplements were purchased
from Invitrogen AG (Basel, Switzerland). The breast carcinoma
cell line MDA-MB-231 was obtained from the European
Collection of Cell Cultures (ECACC) through Sigma-Aldrich,
NCI-H358 lung and HCT 116 colon carcinoma cells were
obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA). MDA-MB-231 and NCI-H358 were
cultured in RPMI medium supplemented with 10% fetal bovine
serum, 10 mM Hepes pH 7.4, and 100 units/ml each of penicillin
and streptomycin. HCT 116 cells were cultured in McCoy
medium containing 10% fetal bovine serum, 10 mM Hepes
pH 7.4 and 100 units/ml each of penicillin and streptomycin. All
cells were grown at 37uC in a humidified atmosphere containing
5% CO2.
SK-1 downregulation in cells was performed using the All
MISSION
R shRNA constructs from Sigma-Aldrich as described
[26]. SK-1 knockdown cells (SK-1 kd) were selected in medium
containing 1 mg/ml puromycin (Santa Cruz Biotechnology). SK-1
overexpressing MDA-MB-231 cells (SK-1 ov) were generated by
stable transfection of the full length SK-1 cDNA cloned into
pcDNA3.1 (Invitrogen AG). Transfection was performed as
recommended by the supplier.
Sphingolipid Quantification by LC/MS/MS
Equal numbers of cells in 6-well plates were scraped in
methanol containing internal C17-S1P and C17-sphingosine,
C17-ceramide standards and subjected to lipid extraction and
mass spectrometry as described [56].
Figure 6. Downregulation of SK-1 compromises M phase arrest and sensitizes cells to taxol. (A) MDA-MB-231 wt and SK-1 kd cells were
treated with various concentrations of taxol or DMSO as vehicle control for 24 h before apoptosis was measured by annexin V staining using flow
cytometry. Data are means 6 SD (n=3); ***p,0.001 compared to DMSO treated cells. (B), detection of phospho-histone H3(Ser10) as a marker of the
mitotic index in MDA-MB-231 wt and SK-1 kd cells at different time points upon treatment with taxol (100 nM). Lysates were subjected to Western
blotting using antibodies against total histone H3 (dilution 1:2000) and phospho-histone H3(Ser10) (dilution 1:1000). The Density of phospho-histone
H3(Ser10) (pH3)/H3 ratio in taxol-treated MDA-MB-231 cells is presented as % of total H3. Each value in the graph represents the mean 6 SD band
density for each group (n=3); ***p,0.001 compared to wt cells. (C) MDA-MB-231 wt cells were treated with taxol (100 nM), the SK-1 inhibitor SK I II
(10 mM), sphingosine (20 mM) or the various combinations for 48 h. DMSO was used as vehicle control. Cell viability was determined in colorimetric
MTT assays. Data are means 6 S.D. (n=3); *p,0.05, ***p,0.001 compared to DMSO treated cells;
#p,0.05,
###p,0.001 compared to the respective
taxol treated cells;
¥¥¥p,0.001 compared to the respective SK I II treated cells.
doi:10.1371/journal.pone.0039209.g006
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The expression of Chk1, SK-1 mRNA was quantified using a
BioRad iQ5-Cycler Detection System (Bio-Rad Laboratories AG,
Reinach, Switzerland). The following primer sequences were used:
human Chk1 forward: AAG CAG TCG CAG TGA AGA TTG
TAG, reverse: TTG CCT TCT CTC CTG TGA CCA TAG;
human SK-1 forward: ACG CTC TGG TGG TCA TGT CTG,
reverse: AGT TGG TCA GGA GGT CTT CAT TGG TTG
CCT TCT CTC CTG TGA CCA TAG; 18 S rRNA forward:
CGA TTC CGT GGG TGG TG GTG, reverse: CAT GCC
AGA GTC TCG TTC GTT ATC. The IQTM5 Optical System
Software (Version 2.0, Bio-Rad) was used to analyze real time and
endpoint fluorescence.
Western Blotting
Cell homogenization, sample preparation and Western blotting
was performed as described [26] using the indicated antibodies.
Cell Viability Assay
Cell viability was measured using the MTT cell proliferation kit
(Roche Diagnostics AG, Rotkreuz, Switzerland) as described by
the manufacturer. Briefly, 5610
4 cells were seeded in 96-well
plates and allowed to adhere overnight. Thereafter, cells were
treated for 48 h with the indicated inhibitors or vehicle (DMSO)
before the MTT reagent was added for 5 h and the absorbance of
formazan was measured using a SpectraMax M2 microplate
reader (Molecular Devices, Bucher Biotech AG, Basel, Switzer-
land).
Colony Formation Assay
Cells were cultured in 60 mm diameter dishes at a density of
700 cells per dish in cell culture medium. After 24 h, cells were
treated with CGP 41-251, Ro 31-8220, sphingosine or DMSO as
vehicle control, and incubated for 14 days to allow colony
formation. Then, cells were washed with ice-cold PBS, air dried,
stained for 30 min with 2% crystal violet, washed with water, and
air dried again. The number of colonies was counted using a
ColCountTM (Mammalian Cell Colony Counter, Oxford Op-
tronix, Oxford, U.K.). Only colonies containing more than 50 cells
were evaluated.
Cell Cycle Analysis
Cells were harvested by trypsinization, washed and fixed in 70%
ethanol overnight at -20uC. Thirty minutes prior to analysis, cells
were resuspended in PBS containing 50 mg/ml propidium iodide
(PI) and 5 mg/ml RNase A. Samples were analyzed using a
FACSCalibur flow cytometer and the Cell Quest software (both
from Becton Dickinson Biosciences, Allschwil, Switzerland). In
each sample, 109000 cells sorted for red fluorescence were
analyzed.
Confocal Microscopy
To analyze nuclear morphology, cells were grown on 12 mm
glass cover slips (BD Biosciences), fixed with 4% paraformalde-
hyde and stained for actin using TRITC-labeled phalloidin and
DAPI for nuclei. The anti-fading fluorescent mounting medium
(Dako) was added and slides were covered with coverslips and
analyzed by confocal laser scanning microscopy (LSM 5 Exciter,
Carl Zeiss MicroImaging GmbH, Jena, Germany). Quantification
of cells and measurement of the largest diameter of nuclei was
performed using a Zeiss LSM Image Browser (Carl Zeiss
MicroImaging GmbH). At least 30 cells in the field were counted
and examined by three independent determinations.
Apoptosis Assay
The fraction of cells with fragmented DNA was quantified from
the SubG1 peak as described under cell cycle analysis. In addition,
apoptotic cells were detected by PI staining and surface binding of
annexin V. To this end, cells were harvested by trypsinization,
washed and resuspended at a concentration of 6610
5 cells/ml in
binding buffer containing 150 mM NaCl, 4 mM KCl,
2.5 mM CaCl2, 1 mM MgSO4, 15 mM HEPES. Cells were
incubated with GFP-coupled annexin V (dilution 1:1000) and PI
(dilution 1:500), analyzed using a FACSCalibur flow cytometer
and the Cell Quest software (Becton Dickinson Biosciences).
Statistics
Statistical analysis of data was performed with Graph Pad Prism
4 (Graph Pad Software Inc., La Jolla, CA, USA). Results are given
as means 6 SD. For two-group analyses Student’s unpaired two-
tailed t-test was used. Statistical analyses of multigroup data were
performed by one way analysis of variance (ANOVA) with
Bonferroni correction. p,0.05 was considered statistically signif-
icant.
Supporting Information
Figure S1 Transduction of carcinoma cell lines with SK-
1 shRNA decreases SK-1 mRNA expression. (A) MDA-MB-
231, NCI-H358, and HCT 116 cells were transduced with
lentiviral SK-1 shRNA to downregulate SK-1 expression (SK-1
kd) or left untreated (wild-type, wt). SK-1 mRNA was measured by
quantitative real-time PCR and data were normalized to 18S
rRNA. Data are means 6 SD (n=3); **p,0.01, ***p,0.001,
compared to wt cells. (B) lysates were prepared from MDA-MB-
231, NCI-H358, and HCT 116 wt and SK-1 kd cells, and
analyzed for SK-2 by Western blotting using antibody against SK-
2 (dilution 1:1000) or GAPDH (dilution 1:2000) as loading control.
(C) cellular ceramide was determined in the genetically modified
SK-1 kd carcinoma cell lines, in the respective wt cells. Lipid
extractions were performed and sphingosine was quantified by
mass spectrometry. Data are means 6 SD. (C) endogenous
sphingosine in the wt carcinoma cell lines upon treatment with the
SK-1 inhibitor SK I II (10 mM) or DMSO as vehicle control for
24 h. Quantification was done as above. Data are means 6 SD
(n=3); *p,0.05, **p,0.01 compared to DMSO treated cells.
(EPS)
Figure S2 PKC isoenzyme expression in MDA-MB-231
cells. Lysates were prepared from MDA-MB-231 wt, SK-1 kd
and SK-1 ov cells, and analyzed for PKC isoenzymes by Western
blotting using specific antibodies against the various PKC proteins
(dilution 1:1000) or GAPDH (dilution 1:2000) as loading control.
(EPS)
Figure S3 Inhibition of SK-1 and sphingosine treatment
increases cells in SubG1 and with 4N and 8N DNA
content. (A) MDA-MB-231 wt cells were seeded in 60 mm
diameter dishes at a density of 36105 cells per dish in cell culture
medium. After 24 h, cells were treated with combination of SK I
II inhibitor and sphingosine, DMSO was used as vehicle control.
After another 24 h, cells were fixed, stained with propidium iodide
and the DNA content was measured by flow cytometry using a
FACSCalibur flow cytometer and the Cell Quest software for data
processing. Data are means 6 S.D. (n=3); *p,0.05, ***p,0.001
compared to the DMSO control values. (B) MDA-MB-231 wt cells
were seeded in 60 mm diameter dishes at a density of 36105 cells
per dish in cell culture medium. After 24 h, cells were treated with
the SK I II inhibitor or sphingosine, DMSO was used as vehicle
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39209control. After another 24 h and 72 h, cells were fixed, stained with
propidium iodide and the DNA content was measured by flow
cytometry using a FACSCalibur flow cytometer and the Cell
Quest software for data processing. Data are means 6 S.D. (n=3);
*p,0.05, **p,0.01, ***p,0.001 compared to the DMSO control
values.
(EPS)
Figure S4 Downregulation of SK-1 in MDA-MB-231 cells
does not affect expression of Beclin 1 and Aurora B.
Lysates were prepared from MDA-MB-231 wt and SK-1 kd cells,
and analyzed for Beclin 1 (Atg 6) (dilution 1:1000), Aurora B
(dilution 1:1000) and GAPDH (dilution 1:2000) as loading control
by Western blotting using specific antibodies.
(EPS)
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